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Abstract
Helicobacter pylori  (H. pylori ) infects more than half 
of the world’s human population, but only 1% to 
3% of infected people consequently develop gastric 
adenocarcinomas. The clinical outcome of the infection 
is determined by host genetic predisposition, bacterial 
virulence factors, and environmental factors. The as-
sociation between H. pylori  infection and chronic active 
gastritis, peptic ulcer disease, gastric cell carcinoma, 
and B cell mucosa-associated lymphoid tissue lym-
phoma has been well established. With the exception 
of unexplained iron deficiency anemia and idiopathic 
thrombocytopenic purpura, H. pylori  infection has no 
proven role in extraintestinal diseases. On the other 
hand, there is data showing that H. pylori  infection 
could be beneficial for some human diseases. The un-
predictability of the long-term consequences of H. py-
lori  infection and the economic challenge in eradicating 
it is why identification of high-risk individuals is crucial. 
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: Helicobacter pylori  (H. pylori ) infects more 
than half of the world’s human population. The as-
sociation between H. pylori  infection and chronic active 
gastritis, peptic ulcer disease, gastric cell carcinoma, 
and B cell mucosa-associated lymphoid tissue lympho-
ma, unexplained iron deficiency anemia and idiopathic 
thrombocytopenic purpura has been well established. 
H. pylori  screening and treatment is a recommended 
gastric cancer risk reduction strategy in high-risk popu-
lations. The unpredictability of the long-term conse-
quences of H. pylori  infection and the economic chal-
lenge in eradicating it is why identification of high-risk 
individuals is crucial. 
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INTRODUCTION
Helicobacter pylori (H. pylori) is a micro-aerophilic, Gram-
negative, slow-growing, spiral-shaped, and flagellated 
organism which infects more than half  of  the world’s 
human population[1]. H. pylori colonization itself  does not 
cause any symptoms, and fewer than 20% of  all infected 
patients will develop symptoms from their infection[2]. 
Approximately 10% of  infected individuals develop pep-
tic ulcer disease, 1% to 3% develop gastric adenocarci-
noma, and less 0.1% [mucosa-associated lymphoid tissue 
(MALT)] develop lymphoma[3].
The outcome of  H. pylori infection may involve a 
combination of  bacterial, host, and environmental fac-
tors. The association between H. pylori infection and 
chronic active gastritis, peptic ulcer disease, gastric cell 
carcinoma, and B cell MALT lymphoma has been well 
established. On the other hand H. pylori infection could 
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be beneficial for humans[2] (Table 1). 
PATHOGENETIC ASPECTS 
Virulence factors of H. pylori
Bacterial virulence factors play a significant role in the 
outcome and progression of  H. pylori infection[4]. The 
linkages of  virulence factors may show how they interact 
with each other[5]. 
The cag pathogenicity island (cag PAI) contains 27-31 
genes flanked by a 31-p direct repeats. H. pylori exhibits 
a high degree of  genetic heterogeneity due to genomic 
rearrangements, gene insertions, and/or deletion[6].
At least 18 cag genes encode components of  the 
bacterial type Ⅳ secretion system, which functions to 
export bacterial protein across the bacterial membrane 
and into host gastric epithelial cells. The presence of  cag 
PAI (cag+) amplifies the risk for severe gastritis, atrophic 
gastritis, and distal gastric cancer in comparison with cag-
deficient (cag-) bacteria[6].
CagA: Cytotoxin-associated gene A product (CagA) 
is translocated into the host cell by the type Ⅳ secre-
tion system. Phosphorylation of  CagA at the glutamate-
proline-isoleucine-tyrosine-alanine (EPIYA) motifs by the 
host Abl and Src kinases results in morphological chang-
es to the cell (the so-called “hummingbird phenotype”). 
Four EPIYA motifs (-A, -B, -C, and -D) are distinguished 
with different degrees of  phosphorylation and geograph-
ical distribution[6]. EPIYA-A and EPIYA -B sites are less 
phosphorylated in comparison with EPIYA-C. EPIYA-C 
is typically found only in strains from Western countries 
(Europe, North America, and Australia), and is an indi-
cator of  gastric cancer risk. EPIYA-D is found in East 
Asian strains. EPIYA-D containing strains induce more 
relief  of  interleukin-8 (IL-8) from gastric epithelial cells[6] 
(Figure 1).
Phospho-CagA interacts with numerous intracellu-
lar effectors, including eukaryotic tyrosine phosphatase 
with sustained activation of  extracellular signal-regulated 
kinases 1 and 2 (ERK ½), Crk adaptor, and C-terminal 
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Table 1  Summary of the pathogenetic and preventive role of Helicobacter pylori
Pathogenetic role Preventive role
Proven Suspected Suspected
Gastro-duodenal diseases Gastro-intestinal diseases Gastroesophageal diseases
   Peptic ulcer    Pancreatic cancer    Gastroesophageal reflux disease
   Gastric cancer    Colorectal adenoma/carcinoma    Esophageal adenocarcinoma
   MALT lymphoma    Liver cirrhosis, hepatocellular carcinoma
Extra-intestinal diseases Extra-intestinal diseases Extra-esophageal diseases
   Immune thrombocytopenic purpura    Laryngeal cancer    Bronchial asthma
   Iron deficiency anemia    Lung cancer
   Metabolic syndrome/insulin resistance
   Cardiovascular diseases/ischemic heart disease
   Chronic urticaria
   Henoch-Schönlein purpura
MALT: Mucosa-associated lymphoid tissue.
Glutamate racemase gene
Cag Ⅱ IS 605 Cag Ⅰ
CagA
ePIYA-containing region
ePIYA site
ePIYA-A
segment
ePIYA-B
segment
ePIYA-C or D
segment
1112 13 1415161718T  S RQPO  M N L   I    H G  F       e        D   C     B
Figure 1  Cytotoxin-associated gene pathogenicity island. CagA: Cytotoxin-associated gene A product; EPIYA: Glutamate-proline-isoleucine-tyrosine-alanine.
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Src kinase[6]. The activation of  ERK and focal adhesion 
kinase with the tyrosine dephosphorylation of  the actin 
binding proteins cortactin, ezrin, and vinculin leads to 
cell elongation[1,6] (Figure 2).
The targets of  non-phosphorylated CagA comprise 
E-cadherin, β-catenin, hepatocyte growth factor receptor 
c-Met, phospholipase C gamma, adaptor protein Grb2, 
kinase partitioning-defective 1b/microtubule affinity-
regulating kinase 2, epithelial tight junction scaffolding 
protein zonula occludens 1, and the transmembrane 
protein junctional adhesion molecule A. The main effects 
are pro-inflammatory and mitogenic cell-cell junction dis-
ruption and loss of  cell polarity that may be important in 
gastric carcinoma development[1,6] (Figures 3 and 4). 
Activity of  CagA on tumor-suppressor pathways has 
also been investigated. CagA is able to modulate the H. 
pylori induced apoptotic signal, but the exact mechanism 
remains to be elucidated. The initial host response up-
regulates p53 expression followed by the proteasomal 
degradation of  p53[8]. 
Almost all cagA+ strains are classified as vacA s1 gen-
otypes (either m1 or m2), whereas almost all cagA- strains 
are classified as the vacA s2/m2 strain (see below)[5]. Spe-
cific vacA genotypes of  H. pylori strains are associated 
with a level of  in vitro cytotoxin activity with clinical con-
sequences[9].
Peptidoglycans: Peptidoglycans translocated by the cag 
secretion system interact with the nucleotide-binding 
oligomerization domain 1 (Nod1) molecule which leads 
to the activation of  nuclear factor κB (NF-κB), pro-
inflammatory secretion of  interleukin-8 (IL-8), and 
β-defensin-2[6,10]. H. pylori enhances the phosphoinosit-
ide 3-kinase Akt signaling pathway, leading to decreased 
apoptosis and increased cell migration. NOD1 ligand 
binding can activate the interferon (IFN)-stimulated gene 
factor 3 signaling cascade, resulting in type Ⅰ IFN pro-
duction usually associated with protection against viral 
infection and possibly other mucosal infections[11].
VacA toxin: The cytotoxin gene vacA is present in all 
strains. The VacA cytotoxin induces the vacuolation, 
gastric epithelial barrier function disruption, disturbance 
of  late endosomal compartments, and modulation of  the 
inflammatory response. VacA reduces the mitochondrial 
transmembrane potential, releases cytochrome c from 
mitochondria, activates caspase 8 and 9, and induces 
apoptosis[6,12].
Binding of  VacA to receptor-type protein tyrosine 
phosphatase (RPTPβ) regulates cell proliferation, dif-
ferentiation, and adhesion, which all play a role in ulcero-
genesis[13].
Variations in vacA gene structure (in the signal s: s1, 
s2, or in the middle regions m: m1, m2) make differences 
in vacuolating activity and specificity. The intermediate 
(i) region also plays role in the vacuolating activity of  H. 
pylori. All s1, m1 strains were classified as i1 (vacuolat-
ing) type, and all s2, m2 strains were classified as i2 (non-
vacuolating) type, while s1, m2 alleles could be i1 or i2. 
A novel intermediate variant (i3) has been identified. The 
fourth pathogenic region is d, a 69-81 bp-region between 
the m and i regions[1,5]. 
The variants in s and m regions seem to be a good 
indicator of  clinical outcomes. However the roles of  i 
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Figure 2  Targets of phosphorylated cytotoxin-associated gene A. Based on the article from Current Opinion in Microbiology, Hatakeyama M, SagA of CagA in 
Helicobacter pylori pathogenesis, 11, 30-37, Copyright (2008), with permission from Elsevier[7]. CagA: Cytotoxin-associated gene A product; NFκB: Nuclear factor κB; 
FAK: Focal adhesion kinase; Csk: C-terminal Src kinase.
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bohydrate structure sialyl-Lewis antigen expressed on 
the gastric epithelium. SabA can mediate the binding of  
H. pylori to neutrophils and erythrocytes, but the patho-
physiological importance of  these findings is uncertain[1]. 
SabA positive status was associated with increased gastric 
cancer risk and a negative status associated with duodenal 
ulceration[12].
The outer inflammatory protein (OipA) has a role 
in the increased expression of  mucosal IL-1, -8, -17, tu-
mor necrosis factor-α (TNF-α), and in gastric mucosal 
inflammation. Upregulation of  matrix metalloproteinase 
1, inhibition of  glycogen synthase kinase 3β, and nuclear 
accumulation of  β-catenin can influence carcinogenesis[6]. 
OipA positive status was significantly associated with 
duodenal ulcer and gastric cancer[12]. 
Others: Duodenal ulcer promoting gene (dupA) product 
induces the production of  IL-8 and -12[5]. DupA may 
enhance duodenal ulceration and /or decrease gastric 
cancer development in some populations[1,5,6].
Variants of  gene encoding flagellar proteins (flaA) of  H. 
pylori may affect motility and colonization, and, therefore, 
the carcinogenic effect[6].
Annexin family members (AnxA1 and AnxA4) are 
involved in epithelial cell membrane repair response 
induced by H. pylori-generated VacA and CagA-indepen-
dent plasma membrane disruption. Plasma membrane 
disruption and AnxA4 can promote cell proliferation[19].
TNF-α-inducing protein (Tipα) binds to cell-surface 
nucleolin and then enters the gastric cancer cells where 
and d regions should be further investigated[5]. The s1, 
m1 strains can induce greater vacuolation, and are as-
sociated with peptic ulcer disease and gastric cancer in 
Western countries, but have no pathogenic role in East 
Asian countries[1,6]. vacA i1 strains were associated with 
gastric cancer in Iranian patients[14], but not in the East 
Asian or Southeast Asian populations[14]. i1 genotype ap-
peared to be a better predictor of  carcinoma-associated 
H. pylori strains than the s or m genotype[15]. In Western 
countries, d1 strains without the deletion of  the d region 
are predictors of  histological inflammation, atrophy, and 
an increased risk of  peptic ulceration and gastric cancer, 
compared with the presence of  the vacA s-, m-, and 
i-region strains[16].
Adhesins and outer membrane proteins: 4% of  the 
H. pylori genome encodes for outer membrane proteins 
(BabA, BabB, SabA, and OipA) which function as adhes-
ins and porins, and are implicated in complement resis-
tance and immune regulation[17].
The blood group antigen binding adhesin BabA 
is thought to mediate host-bacterial interactions and 
maintain colonization of  the H. pylori targeting human 
Lewis-b surface epitopes[18,19]. The babA2 gene is associ-
ated with duodenal ulcer and gastric cancer. When in 
conjunction with cagA and vacA s1 alleles (“triple-pos-
itive strains”), it is associated with a greater risk of  the 
more severe duodenal ulcer and gastric adenocarcinoma 
in Western populations[1,6,19]. 
Sialic acid-binding adhesin (SabA) binds to the car-
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TNF-α and chemokine gene expressions are induced by 
NF-κB activation in a cag PAI independent manner[20].
Bacterial factors like urease, AmiE, AmiF, hydrog-
enase, and arginase are essential for H. pylori survival in 
the acidic gastric environment[4].
Immune response to H. pylori : The host’s innate and 
adaptive immune system plays a crucial role in the initia-
tion and progression of  H. pylori infection[21]. 
Innate immunity effectors and a complex mixture of  T 
helper (Th) 1, Th17, and regulatory T cells (Treg) adaptive 
immunity effectors are involved in H. pylori infection[22].
H. pylori initially targets gastric epithelial cells which 
form part of  the innate immune response via signaling 
through pattern recognition receptors, such as Toll-like 
receptors (mainly TLR2)[21]. 
The neutrophil-activating protein of  H. pylori polar-
izes Th1 cells, stimulating IL-12 and IL-23 secretion 
from neutrophils and macrophages. Th1 cytokines, such 
as gamma interferon (IFN-γ) and TNF-α, can increase 
the release of  pro-inflammatory cytokines and augment 
apoptosis induced by H. pylori[22,23]. 
IL-17 expressing Th17 cells are important in the pro-
inflammatory immune response to H. pylori. Th17 cells 
produce Il-17, IL-21, and IL-22 cytokines[6]. H. pylori in-
fected macrophages produce IL-6, IL-23, and transform-
ing growth factor (TGF)-β, which are required for Th17 
cell development and maintenance[6,21]. The literature on 
Th1 and Th17 H. pylori-associated gastric pathology is 
confusing and requires intensive investigation[6].
Tregs (formerly suppressor T cells) are also implicated 
in the pathogenesis of  H. pylori infection. TGF-β and 
IL-18 are responsible for Treg development[21]. H. pylori-
specific Tregs suppress memory T cell responses that 
prolong the infection[6]. Tregs suppress the inflammatory 
reaction driven by IL-17, thereby also favoring bacterial 
persistence[24].
Antimicrobial defense of  macrophages is nitric oxide 
(NO) dependent. H. pylori’s arginase enzyme can compete 
with macrophages for the inducible nitric oxide synthase 
(iNOS) substrate L-arginine so that host NO production 
is impaired; this leads to enhanced bacterial survival. H. 
pylori can evade macrophage phagocytosis. VacA protein 
prevents the fusion of  phagosomes with lysosomes need-
ed for phagocytosis. Fused phagosomes contain large 
numbers of  live bacteria[6]. 
The role of  B cells in the host response to H. pylori 
has been suggested[21]. Immunoglobulin (Ig) G and IgA 
antibody release from B cells in response to H. pylori 
may be involved in protective immunity, however it 
was suggested this antibody-mediated response may be 
counterproductive. B cells can also produce autoreactive 
antibodies that may be pathogenic[6]. B cell activation and 
survival may have implications for MALT lymphoma de-
velopment[6]. 
CLINICAL ASPECTS
Gastroduodenal diseases
Peptic ulcer: Some H. pylori colonized individuals may 
develop corpus gastritis associated with gastric hypo-
chlorhydria, gastric atrophy, gastric ulcer, and an increased 
risk of  gastric cancer. Conversely, others may develop 
antral-predominant gastritis, which is associated with gas-
tric hyperchlorhydria and an increased risk of  duodenal 
ulcer[8,25].
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Since the discovery of  H. pylori in the 1980s, the avail-
ability of  effective eradication therapy has led to a decline 
in recurrent peptic ulcer disease and its complications. 
The pathogenetic role of  H. pylori in 90% of  duodenal 
ulcers and 80% of  gastric ulcers is proven[26,27]. Effective 
eradication decreased the yearly recurrence rate of  duo-
denal and gastric ulcers from 80% and 60%, respectively, 
to less than 5%[28].
Gastric cancer: H. pylori is a class I carcinogen in hu-
mans[1]. It is considered to be the most common aetio-
logical factor of  infection-related cancers (followed by 
human papilloma, hepatitis B and C, Epstein-Barr, hu-
man immunodeficiency, and human herpesvirus-8)[1,29]. 
H. pylori infection-related cancer represents 5.5% of  the 
global cancer burden[6]. 
Gastric cancer develops in 2.9% of  H. pylori infected 
patients[30]. H. pylori infection is responsible for about 
75% of  all non-cardia gastric cancers and 63.4% of  all 
stomach cancers worldwide[1]. H. pylori infection also plays 
a fundamental role in non-cardia gastric carcinogenesis, 
but its association with cardia cancer is still uncertain[31].
The prevalence of  infection is statistically significantly 
much higher in patients with intestinal-type gastric cancer 
(89.2%) compared to the diffuse-type (31.8%)[32]. H. pylori 
infection is regarded as the trigger of  intestinal-type gastric 
adenocarcinoma[33]. According to Correa and Piazuelo, 
intestinal-type gastric carcinogenesis progresses as follows: 
normal gastric mucosa - no atrophic gastritis - multifocal 
atrophic gastritis without intestinal metaplasia - intestinal 
metaplasia of  complete (small intestine) type - low-grade 
dysplasia - high-grade dysplasia - invasive adenocarcino-
ma[34]. Altered cell proliferation, apoptosis, epigenetic 
modifications to the tumor suppressor genes, onco-
gene activation, and dysregulation of  DNA repair may 
occur and eventually lead to inflammation-associated 
carcinogenesis[35].
Eradication of  H. pylori infection decreases the risk 
of  premalignant lesions and gastric cancer in infected 
individuals[36-38]. Follow-up endoscopy and histology is 
crucial, even in patients with apparently non-malignant 
gastric ulcers, in improving the malignancy detection rate 
in populations with a high prevalence of  gastric cancer[39].
H. pylori plays a role in the development and pro-
gression of  gastric (MALT) lymphoma[40]. The average 
prevalence of  H. pylori infection in MALT lymphoma was 
79%; it was higher in low-grade (79%) than in high-grade 
(60%) cases[41]. Treatment for localized stage Ⅰ gastric 
MALT lymphoma with H. pylori infection is eradication[40]. 
Eradication of  H. pylori resulted in a complete remission in 
60%-80% of  patients with MALT lymphoma[42,43], and a 
10-year sustained remission in up to 64% of  cases[44].
The carcinogenic effect of  H. pylori can be modified 
by dietary and environmental factors. H. pylori infection 
is more frequent in less developed Asian countries (e.g., 
India, Bangladesh, Pakistan, and Thailand) in comparison 
with the more developed Asian countries (e.g., Japan and 
China). However, the frequency of  gastric cancer is para-
doxically very low in these less developed regions than 
in Japan and China (the so-called “Asian enigma”)[33,45]. 
Several other large populations with high infection preva-
lence show a very low rate of  gastric cancer. The so-
called “African enigma” remains unexplained as well, but 
it does verify that not all H. pylori infected patients have 
an increased risk of  gastric cancer[32,33,46].
Host and environmental factors also affect the devel-
opment of  gastroduodenal diseases in H. pylori infected 
individuals[6,47]. Individuals with a high-expression of  IL-
1β polymorphisms (C-T or T-C transitions, at positions 
-511, -31, and +3954 base pairs from the transcriptional 
start site) have an increased risk for hypochlorhydria, gas-
tric atrophy, and distal gastric adenocarcinoma in com-
parison with low-expression polymorphisms; they have 
no effect on cancers associated with high acid exposure 
such as esophageal adenocarcinomas and some cardia 
cancers[47,48]. The combined effects of  pro-inflammatory 
IL-1 genotypes and H. pylori bacterial virulence factors 
have been reported[48].
Gene polymorphisms (-308 G > A) of  the pro-in-
flammatory cytokine TNF-α that increase the expression 
of  the cytokine and polymorphisms (promoter polymor-
phisms at positions -592, -819, and -1082) that reduce 
the production of  the anti-inflammatory cytokine (IL-10) 
have been associated with an increased risk of  distal gas-
tric cancer[48-50].
The effects of  pro-inflammatory genotypes (IL-1β, 
TNF-α and IL-10) are additive[6,50]. 
High dietary salt intake increases the risk of  gastric 
cancer by directly damaging gastric mucus and mucosa, 
improving temporary epithelial proliferation, increasing 
the incidence of  endogenous mutations, upregulating cy-
tokine production, and H. pylori gene expression modula-
tion, especially that of  virulence factors[51-53]. 
Co-infection with helminths (Ascaris lumbricoides) and 
Toxoplasma gondii reduces the severity of  H. pylori-induced 
gastritis via a reduced Th1 response with higher levels of  
Th2 cytokines[54].
Fruit and vegetables are rich sources of  carotenoids, 
vitamin C, folate, and phytochemicals, which may modu-
late xenobiotic-metabolizing enzymes and have antioxi-
dant activity, thereby playing a preventive role in carcino-
genesis[6,55-57].
Smoking is an established risk factor for gastric can-
cer. Swallowed carcinogenic substances (nitrosamine 
and other nitroso compounds), greater concentrations 
of  smoking-related DNA adducts in the gastric mucosa, 
lower levels of  free radical scavengers (ascorbic acid and 
β-carotene), and increased mRNA expression of  chemo-
kines in the gastric mucosa are in the background[58]. 
Pancreatic cancer
Epidemiological studies have suggested that H. pylori 
might be involved in the pathogenesis of  pancreatic can-
cer (OR = 1.87, 2.1), however results are inconsistent[59,60]. 
A meta-analysis showed significant association between 
H. pylori seropositivity and development of  pancreatic 
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cancer (pooled adjusted OR = 1.38), but further research 
is needed to confirm this result[61,62].
Despite good scientific reasoning for the involvement 
of  H. pylori in pancreatic diseases, direct pancreatic infec-
tion seems unlikely[63] (Table 2).
Colorectal adenoma/carcinoma
On the basis of  the epidemiological results showing 
high mortality rates from gastric and colorectal cancer in 
similar areas, it can be speculated that gastric cancer and 
colorectal cancer have common risk factors like H. pylori 
infection[68]. Although the role of  H. pylori in colorectal 
carcinogenesis has been widely examined, the association 
has remained inconclusive[69]. Several studies demon-
strated conflicting positive and negative associations[68,69]. 
A meta-analysis showed that H. pylori infection was asso-
ciated with an increased risk of  colorectal adenoma (OR 
= 1.66) and colorectal cancer (OR = 1.39), however there 
was significant heterogeneity among the studies[70]. The 
inconsistent results might be due to sample bias, small 
sample size, varying frequencies of  cagA+ strains in the 
study population, incomplete colonoscopies, and evalua-
tion of  H. pylori infection with the IgG serum test[69]. 
H. pylori was detected in colorectal carcinoma tissue in 
a pilot study[71]. Higher prevalence was proven in adeno-
ma and colorectal cancer compared with control[72,73]. H. 
pylori was more prevalent in moderate/severe dysplastic 
adenomas compared with mild dysplasia, and in tubular 
and tubulovillous adenoma compared with villous type[72].
The pathogenetic mechanisms of  H. pylori induced 
colorectal carcinogenesis are not fully understood[69] 
(Table 2). However, not every study confirms the cor-
relation between atrophic gastritis, hypergastrinemia, 
and colorectal cancer[68]. Conversely, atrophic gastritis 
and hypergastrinemia demonstrated a significant eleva-
tion in the odds ratio (3.15) for rectal cancer[68]. Overall, 
chronic atrophic gastritis did not seem to contribute to 
an increase in colorectal adenoma risk. Chronic atrophic 
gastritis and its progression appear to further increase 
the risk for proximal colorectal adenoma formation[77]. 
The inconsistent results correlating hypergastrinemia 
and colorectal carcinogenesis may be explained by the 
fact that gastrin precursors (progastrin and glycine-ex-
tended gastrin) act as important promoters of  colorectal 
carcinogenesis, but cannot be measured by most com-
mercially available assays[77,78].
Concomitant H. pylori infection with metabolic syn-
drome further increases the possibility of  colorectal 
adenoma formation; however the pathomechanism for 
this possible association is still unclear[69]. Insulin might 
exert proliferative effects on colonic tumor cells directly 
or indirectly via the insulin-like growth factor pathway[79]. 
Chronic inflammation, increased pro-inflammatory 
cytokine production, and decreased anti-inflammatory 
adiponectin production might be associated with carci-
nogenesis[69,80]. Triglycerides are energy sources for cancer 
cell growth and are linked with increased synthesis of  bile 
acids, which have a carcinogenesis promoting effect[81]. 
Extra-intestinal diseases
It has been shown that H. pylori may play a potential 
pathogenic role in extra-intestinal diseases via multiple 
mechanisms[82]. Atrophic gastritis caused by infection, 
an increase in gastric vascular permeability and therefore 
increased exposure to alimentary antigens, release of  in-
flammatory mediators, and systemic immune responses 
(auto-immunity, pro-inflammatory substances, and im-
Table 2  Putative pathomechanisms of Helicobacter pylori
Disease Putative pathomechanisms 
Pathogenetic role
   Pancreatic cancer Inflammatory cytokine ↑[61]
Angiogenic factors ↑[61]
Reactive oxygen species ↑[61]
Somatostatin synthesis ↓[64,65]
Secretin release ↑[64,65]
Basal pancreatic bicarbonate output ↑[64,65]
Bacterial overgrowth, production of 
N-nitroso compounds ↑[66]
Absorption of antioxidants ↓[67]
   Colorectal adenoma/
   carcinoma
Direct damage[69]
Inflammation ↑[69]
Bacterial overgrowth, bacterial fermentation 
(ammonia)↑[69-71,74,75]
NO release ↑[76]
Hypergastrinemia[68,69]
   Hepatobiliary disease Ammonia ↑[90]
Endotoxemia[90]
Inflammation ↑[90]
Hepatic fibrosis ↑[87]
Hepatoma cell adhesion and invasion ↑[91]
   Laryngeal cancer Sensitivity to smoke and dust ↑[92]
Cell proliferation ↑[92]
Apoptosis ↓[92]
   Lung cancer Direct damage[97]
Sensitivity to smoke and dust ↑[98] 
Inhalation of gastrin and urea[95]
Hypergastrinemia[94]
Activation of docking protein p130cas[95]
Inflammation ↑[94]
   Insulin resistance/
   metabolic syndrome
Inflammation ↑[103,105]
Vasoconstrictor factors ↑[103,105]
Adiponectin ↓[104]
   Atherogenesis Inflammation ↑[108]
Autoimmunity[108]
Fibrinogen ↑[112]
Platelet aggregation ↑[114]
   Chronic urticaria Vascular permeability ↑[83]
Complement consumption ↑[83]
Pathogenetic antibodies ↑[83]
   Henoch-Schönlein 
   purpura
IgA ↑[82]
Cryoglobulins ↑[82]
C3 ↓[82]
Possible preventive role
   Gastroesophageal 
   reflux disease
Sympathetic tone ↑[128]
Cholinergic stimulation[128]
   Esophageal 
   adenocarcinoma
Sympathetic tone ↑[128]
Cholinergic stimulation[128]
Acid production ↓[129]
   Bronchial asthma Polarization of Th-1 ↓[131]
Allergic Th-2 response ↓[131]
Tregs ↓[132,133]
Interleukin-1 receptor associated kinase M 
(IRAK-M) ↑[133]
↑: Increase; ↓: Decrease.
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mune complex formation induced by molecular mimicry 
and cross-reactive antibodies) have been suspected in the 
background[82,83].
With the exception of  unexplained iron deficiency 
anemia (evidence level 1a) and idiopathic thrombocyto-
penic purpura (evidence level 1b), H. pylori infection has 
no proven role in other extra-intestinal diseases[82,84,85]. 
Hepatobiliary diseases
Helicobacter DNA has been detected in hepatic tissues 
from patients with various hepatobiliary diseases, hepati-
tis C virus-related chronic hepatitis, cirrhosis, and hepa-
tocellular carcinoma (HCC)[86,87]. The association between 
H. pylori and Child-Pugh classification is inconsistent[87]. 
It can be proposed that H. pylori infection may play a role 
in hepatic carcinogenesis as well[88]. The odds ratio for 
the association between H. pylori infection and the risk of  
HCC was 13.63[89] (Table 2).
Respiratory tract disorders
Laryngeal cancer: Colonization of  bacteria in the upper 
aerodigestive tract was confirmed, however the relation-
ship between H. pylori infection and laryngeal cancer risk 
have produced conflicting results. Meta-analysis showed a 
2.03-fold increased risk[92].
H. pylori was detected in larynx cancerous tissue. The 
presence of  the cagA gene in larynx cancer tissues signifi-
cantly decreased survival rate and increased the possibility 
of  disease recurrence[93] (Table 2).
Lung cancer: The results of  previous studies of  H. py-
lori seropositivity and lung cancer are inconclusive[94], with 
an odds ratio between 1.24 and 17.78 on the basis of  the 
epidemiological studies[95]. The NHANES study observed 
an inverse association between H. pylori and lung cancer 
in older participants, with a significant inverse association 
for cagA+ strains; this was without histological examina-
tion[96]. A case-control study found no evidence of  an 
association between H. pylori and lung cancer in Finish 
male smokers. Neither overall H. pylori seropositivity nor 
CagA-specific H. pylori seropositivity were associated with 
lung cancer[94]. Causal relationships must be confirmed 
with exact determination of  smoking status[95] (Table 2).
Insulin resistance and metabolic syndrome
Epidemiological studies showed significant associations 
with metabolic syndrome (OR = 1.39)[99,100]. Furthermore, 
multiple linear regression analysis showed that H. pylori 
seropositivity was significantly associated with higher 
systolic blood pressure, lower high-density lipoprotein 
(HDL)-cholesterol level, and higher low-density lipo-
protein (LDL)-cholesterol level[99]. It has been suggested 
that H. pylori eradication could lead to an improvement 
of  atherogenic blood lipid profile, insulin resistance, and 
low-grade inflammation, which were deduced from a de-
creased C-reactive protein level[101]. Other studies did not 
find an association between H. pylori infection and insulin 
resistance[102,103]. 
The relationship between H. pylori infection and meta-
bolic syndrome is both poorly understood[104] (Table 2) 
and controversial[106-108]. 
Cardiovascular diseases
Studies investigating the pathogenetic role of  H. pylori 
in cardiovascular diseases have produced conflicting re-
sults[108-111]. A meta-analysis of  18 epidemiological studies 
involving 10,000 patients did not find any positive associ-
ation between H. pylori and cardiovascular risk factors and 
coronary heart diseases[112]. A higher prevalence of  more 
virulent cagA+ H. pylori was reported in patients with 
ischemic heart disease, unstable angina, acute myocardial 
infarction, and restenosis after percutaneous transluminal 
coronary angioplasty and essential hypertension[108,111,113].
Evidence on the relationship between H. pylori infec-
tion and ischemic heart disease is weak, with some incon-
clusive, albeit plausible, mechanisms (Table 2). There are 
also no adequate interventional studies done to demon-
strate that H. pylori eradication is associated with a lower 
incidence of  ischemic heart disease[108].
Dermatological disorders
Chronic urticaria: A correlation between H. pylori infec-
tion and chronic urticaria has been suggested (Table 2). H. 
pylori eradication in patients with chronic urticaria leads to 
symptomatic improvement in some patients, while others 
showed no improvement[83].
Hematological disorders
Immune thrombocytopenic purpura: The prevalence 
of  H. pylori infection in patients with immune thrombo-
cytopenic purpura (ITP) is significantly higher than that 
in age- and gender-matched controls[108,115,116]. The most 
plausible mechanism is cross-mimicry involving H. py-
lori, platelet antigens, and infected host factors (antibody 
production cross-reacts with platelet glycoprotein anti-
gens)[108,117].
Eradication of  H. pylori results in an increasing plate-
let count in nearly half  of  infected ITP patients, although 
geographical differences in the efficacy of  eradication 
were also presumed[83,115,116]. The European Helicobacter 
Study Group consensus in 2012 and the Second Asia-Pa-
cific Consensus Guidelines have recommended H. pylori 
infection eradication in patients with chronic idiopathic 
thrombocytopenic purpura[84,85]. However, larger random-
ized controlled trials with long-term follow-up are still 
required before a firm conclusion can be drawn[108].
Henoch-Schönlein purpura: A study in China found 
increasing evidence suggesting that Henoch-Schönlein 
purpura (HSP), especially abdominal HSP, might be asso-
ciated with H. pylori infection (OR = 4.62); this underlines 
the necessity of  screening H. pylori infection in children 
with HSP with gastrointestinal manifestations[82]. 
It was found that eradication of  H. pylori infection 
resulted in prompt resolution of  the HSP, or at least pre-
vented its recurrence[118].
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More investigations are needed to confirm the patho-
genetic role of  H. pylori in HSP (Table 2). HSP children 
with serious gastrointestinal symptoms must be screened 
and treated for H. pylori infection[82]. 
Iron deficiency anemia: Several epidemiological studies 
have shown lower ferritin levels among patients with H. 
pylori infection, although there were studies that produced 
a negative association[108]. Meta-analyses showed an as-
sociation between H. pylori infection and iron deficiency 
anemia (IDA)[119,120]. H. pylori eradication improves iron 
absorption[121].
Possible pathomechanisms are: increased iron loss 
due to active hemorrhage secondary to gastritis, peptic 
ulcer, gastric cancer, reduced iron absorption caused by 
achlorhydria induced by chronic pangastritis, reduced 
secretion of  ascorbic acid to the gastric mucosa, and 
iron utilization for protein synthesis by the bacterium for 
colonization in the host environment[122]. Elevated serum 
prohepcidin might also indicate the role of  inflammation 
in its aetiology[123].
Testing and eradication of  H. pylori for unexplained 
IDA are supported by the current evidence and approved 
by the Maastricht Ⅳ Consensus and the Second Asia-Pa-
cific Consensus Guidelines[84,85]. However, larger sample 
randomized controlled trials are necessary to clarify the 
reason why only a small proportion of  H. pylori-positive 
patients develop IDA[108].
Possible beneficial clinical consequences of H. pylori 
infection
Gastroesophageal reflux disease/esophageal adeno-
carcinoma: A meta-analysis showed that H. pylori infec-
tion displays a negative association with the development 
of  endoscopic gastroesophageal reflux disease (GORD). 
Eradication of  the infection may be a risk factor for de-
velopment of  de novo GORD[124].
H. pylori infection protects against gastroesophageal 
reflux[2]. H. pylori-induced corpus gastritis and profound 
suppression of  gastric acid secretion have also been 
shown to prevent patients from developing GORD[125]. 
cagA+ H. pylori strains have a more protective effect 
against GORD[126], and it was found that H. pylori infec-
tion was inversely associated with Barrett’s esophagus[127].
The Maastricht consensus Ⅳ confirmed a negative 
association between the prevalence of  H. pylori and the 
severity of  GORD. The consensus stated that H. pylori 
status exerts no effect on symptom severity, recurrence, 
or treatment efficacy in GORD. H. pylori eradication does 
not exacerbate pre-existing GORD or affect treatment 
efficacy[85]. 
Esophageal adenocarcinoma risk due to H. pylori in-
fection was 0.58-fold, and squamous cell carcinoma risk 
was 0.80-fold compared with that of  controls. Compared 
with cagA- H. pylori, cagA+ H. pylori markedly decreased 
esophageal cancer risk[129].
The underlying mechanism in the background of  the 
protective effect of  H. pylori against GORD is not fully 
understood (Table 2). 
H. pylori infection acts as neither a preventive factor 
nor a risk factor for squamous cell carcinoma. This dis-
crepancy might be due to the relatively small number and 
heterogeneity of  the included studies[129]. 
There is further need to assess the benefits of  H. py-
lori in connection with GORD and its complications.
Bronchial asthma: An infection in the early phase of  
life is essential for the normal maturation of  the immune 
system, achieving a balance between T-helper type 1 (pro-
tective immunity) and T-helper type 2 (allergic diseases) 
cytokine responses, which can reduce the risk of  atopy 
later[129].
H. pylori infection might play a role in the develop-
ment of  chronic bronchitis, bronchiectasis, tuberculosis, 
and lung cancer[130]. Moreover, H. pylori might have an in-
fluence on the developing immune system, which might 
reduce the risk of  asthma in later life[131].
The associations between H. pylori and asthma were 
contradictory. Inverse associations were reported, but 
other studies demonstrated different results[131]. A meta-
analysis found weak evidence (OR = 0.81, 0.84) for an 
inverse association between H. pylori infection and asthma 
in children and adults, respectively[131,132]. Another meta-
analysis failed to prove a significant association between 
H. pylori infection and asthma risk[130].
The mechanism of  the preventive effect of  H. pylori 
on asthma has been unambiguous (Table 2). 
It seemed that H. pylori infection (especially cagA+ 
strains) may prevent children from developing asthma, 
but must be studied in the future[131] due to the inconsis-
tent result[134].
CONCLUSION
The clinical outcome of  H. pylori infection is determined 
by host genetic predisposition, bacterial strain factors, and 
environmental factors[1]. Bacterial virulence factors (VacA, 
CagA) can modulate the immune response involved in 
the initiation of  the carcinogenesis in the stomach. Host 
genetic factors including IL-1β, IL-10, and TNF-α influ-
ence the inflammatory response and the exasperation of  
mucosal damage. Environmental factors, including salt 
intake and smoking tobacco, are well-known harmful 
aetiological factors. The ingestion of  fruit and vegetables 
has some protective effect[135].
The mechanisms of  H. pylori-associated gastric car-
cinogenesis are still poorly defined; further recognition 
may provide possibilities to develop effective strategies 
for gastric cancer prevention and treatment[1]. 
Indications for H. pylori therapy have been extended 
and now include idiopathic thrombocytopenic purpura, 
iron deficiency anemia, and vitamin B12 deficiency. New 
data are presented on the role of  H. pylori in neurodegen-
erative disorders and in metabolic syndrome. H. pylori is 
associated with a small increase in the risk for colorectal 
adenoma and colon cancer[80] (Table 3). 
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H. pylori screening and treatment is a recommended 
gastric cancer risk reduction strategy in high-risk popula-
tions. In low-risk populations for gastric cancer, H. pylori 
screening is not recommended[84]. The removal of  H. 
pylori from a large section of  the population may be eco-
nomically difficult, and the long-term consequences are 
still unpredictable. Identification of  high-risk individuals 
is thus very important[40].
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